Email Alert RSS
Volume 11 Issue 5
Sep.  2020
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2020  >  11(5): 601-605
Guo-yang ZHENG, Yu-shi ZHANG, Han-zhong LI. Application of Cytoreducive Nephrectomy in the Treatment of Metastatic Renal Cell Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 601-605. doi: 10.3969/j.issn.1674-9081.2020.05.017
Citation: Guo-yang ZHENG, Yu-shi ZHANG, Han-zhong LI. Application of Cytoreducive Nephrectomy in the Treatment of Metastatic Renal Cell Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 601-605. doi: 10.3969/j.issn.1674-9081.2020.05.017
shu

Application of Cytoreducive Nephrectomy in the Treatment of Metastatic Renal Cell Carcinoma

doi: 10.3969/j.issn.1674-9081.2020.05.017

  • Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author: ZHANG Yu-shi  Tel: 86-10-69152510, E-mail: zhangyushi@126.com
  • Received Date: 2019-07-02
  • Publish Date: 2020-09-30
    Abstract
  • In the interferon era, cytoreductive nephrectomy was recommended for the treatment of patients with good performance status that were diagnosed with metastatic renal cell carcinoma. In recent years, in spite of the wide application of targeted therapy, cytoreductive nephrectomy is still an important part of the treatment of metastatic renal cell carcinoma. With the publication of two prospective studies, CARMENA and SURTIME, the role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma should be revalued. Based on the results and related considerations of above two studies, we reviewed recent progress in the application of cytoreductive nephrectomy in metastatic renal cell carcinoma.
    • FullText(HTML)
  • loading
    • References(23)
  • [1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69:7-34. doi:  10.3322/caac.21551
    [2] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63:11-30. doi:  10.3322/caac.21166
    [3] Capitanio U, Bensalah K, Bex A, et al. Epidemiology of Renal Cell Carcinoma[J]. Eur Urol, 2019, 75:74-84. doi:  10.1016/j.eururo.2018.08.036
    [4] Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer[J]. N Engl J Med, 2001, 345:1655-1659. doi:  10.1056/NEJMoa003013
    [5] Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial[J]. Lancet, 2001, 358:966-970. doi:  10.1016/S0140-6736(01)06103-7
    [6] Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis[J]. J Urol, 2004, 171:1071-1076. doi:  10.1097/01.ju.0000110610.61545.ae
    [7] Conti SL, Thomas IC, Hagedorn JC, et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era[J]. Int J Cancer, 2014, 134:2245-2252. doi:  10.1002/ijc.28553
    [8] 盛锡楠, 郭军.晚期肾癌:治疗进展及展望[J].协和医学杂志, 2019, 2:148-151. http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_xhyx201902013&dbid=WF_QK
    [9] García-Perdomo HA, Zapata-Copete JA, Castillo-Cobaleda DF. Role of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis[J]. Investig Clin Urol, 2018, 59:2-9. doi:  10.4111/icu.2018.59.1.2
    [10] Bex A, Ljungberg B, van Poppel H, et al. The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016[J]. Eur Urol, 2016, 70:901-905. doi:  10.1016/j.eururo.2016.07.005
    [11] Hanna N, Sun M, Meyer CP, et al. Survival analyses of Patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: A National Cancer Data Base Study[J]. J Clin Oncol, 2016, 34:3267-3275. doi:  10.1200/JCO.2016.66.7931
    [12] Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium[J]. Eur Urol, 2014, 66:704-710. doi:  10.1016/j.eururo.2014.05.034
    [13] Kutikov A, Uzzo RG, Caraway A, et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy[J]. BJU Int, 2010, 106:218-223.
    [14] 郑克文, 李汉忠, 李永强.转移性肾癌靶向药物治疗的预后因素和相关模型[J].中国医学科学院学报, 2014, 36:450-453. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgyxkxyxb201404018
    [15] Heng DY, Xie WL, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study[J]. Lancet Oncol, 2013, 14:141-148. doi:  10.1016/S1470-2045(12)70559-4
    [16] Méjean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma[J]. N Engl J Med, 2018, 379:417-427. doi:  10.1056/NEJMoa1803675
    [17] Bex A, Mulders P, Jewett M, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial[J]. JAMA Oncol, 2019, 5:164-170. doi:  10.1001/jamaoncol.2018.5543
    [18] Silberstein JL, Adamy A, Maschino AC, et al. Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC)[J]. BJU Int, 2012, 110:1276-1282. doi:  10.1111/j.1464-410X.2012.11103.x
    [19] Rini BI, Garcia J, Elson P, et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery[J]. J Urol, 2012, 187:1548-1554. doi:  10.1016/j.juro.2011.12.075
    [20] Karam JA, Devine CE, Urbauer DL, et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma[J]. Eur Urol, 2014, 66:874-880. doi:  10.1016/j.eururo.2014.01.035
    [21] 郑国洋, 李汉忠, 张玉石.PD-1/PD-L1通路相关的肾癌免疫治疗研究进展[J].中华医学杂志, 2017, 97:958-960. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyx201712019
    [22] Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2015, 373:1803-1813. doi:  10.1056/NEJMoa1510665
    [23] Powles T, Albiges L, Staehler M, et al. Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer[J]. Eur Urol, 2018, 73:311-315. doi:  10.1016/j.eururo.2017.11.016
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (233) PDF downloads(8) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return